Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab

Journal of Neurology

Volumn 255, Issue 2, 2008, Pages 295-296

  El Maalouf, G ^a   Mitry, E ^a   Lacout, A ^b   Lievre A ^a   Rougier, P ^a  

^a HÔPITAL AMBROISE PARÉ   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID;

ADULT; BRAIN REGION; BRAIN STEM INJURY; CASE REPORT; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; DYSARTHRIA; FEMALE; HUMAN; HYPERTENSION; LETTER; LEUKOENCEPHALOPATHY; METASTASIS; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BRAIN DISEASES; BRAIN STEM; COLONIC NEOPLASMS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 40149097100     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-008-0692-2     Document Type: Letter

References (12)

1. Hinchey J, Chaves C, Appignani B, et al. (1996) A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334(8):494-500
2. Nagata M, Maeda M, Tsukahara H, Maier SE, Takeda K (2004) Brain stem hypertensive encephalopathy evaluated by line scan diffusion-weighted imaging. AJNR Am J Neuroradiol 25(5):803-806
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342
4. Ozcan C, Wong SJ, Hari P (2006) Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354(9):980-982; discussion 980-982
5. Glusker P, Recht L, Lane B (2006) Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354(9):980-982; discussion 980-982
6. Allen JA, Adlakha A, Bergethon PR (2006) Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 63(10):1475-1478
7. Tjoa ML, Levine RJ, Karumanchi SA (2007) Angiogenic factors and preeclampsia. Front Biosci 12:2395-2402
8. Levine RJ, Maynard SE, Qian C, et al. (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350(7):672-683
9. Maynard SE, Venkatesha S, Thadhani R, Karumanchi SA (2005) Soluble Fmslike tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res 57(5 Pt 2):1R-7R
10. Venkatesha S, Toporsian M, Lam C, et al. (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12(6):642-649
11. Bdolah Y, Sukhatme VP, Karumanchi SA (2004) Angiogenic imbalance in the pathophysiology of preeclampsia: newer insights. Semin Nephrol 24(6):548-556
12. Folkman J (2007) Is angiogenesis an organizing principle in biology and medicine? J Pediatr Surg 42(1):1-11